Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

Core Viewpoint - Oncolytics Biotech Inc. will voluntarily delist its common shares from the Toronto Stock Exchange (TSX) effective August 22, 2025, while maintaining its listing on the Nasdaq [1][2]. Group 1: Delisting Details - The delisting from TSX is deemed beneficial for the company and its shareholders, allowing shares to continue trading on Nasdaq under the symbol "ONCY" [2]. - Canadian shareholders can trade their shares on Nasdaq through U.S.-registered broker-dealer affiliates [2]. - Oncolytics will remain a reporting issuer in Canada, and shareholder approval for the delisting is not required under TSX regulations [2]. Group 2: Company Overview - Oncolytics is a clinical-stage biotechnology company focused on developing pelareorep, an immunotherapeutic agent that has shown promising results in treating various cancers, including pancreatic and breast cancers [3][4]. - Pelareorep works by converting "cold" tumors into "hot" tumors, thereby activating immune responses against cancer [3]. Group 3: Strategic Focus - The company is advancing pelareorep in combination with chemotherapy and checkpoint inhibitors for metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA [4]. - Oncolytics is actively seeking strategic partnerships to enhance development and commercial impact [4]. Group 4: Future Considerations - Oncolytics will cease to be treated as a Foreign Private Issuer under U.S. federal securities laws effective January 1, 2026, and is contemplating re-domiciling to the U.S. [6]. - The company believes that the costs associated with maintaining a secondary listing on TSX do not justify the benefits, given its focus on the U.S. market and shareholder base [6].